TristelTSNLF 97 ROC (Joel Greenblatt) % is 62.36% as of Dec. 2025, which is 5% below its 10-year median of 65.33. GuruFocus rates TSNLF with a GF Score™ of 97/100 and a GF Value™ of $6.80 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 839 Medical Devices & Instruments companies, Tristel ranks better than 91.66% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Tristel's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 62.36%.
The historical rank and industry rank for Tristel's ROC (Joel Greenblatt) % or its related term are showing as below:
TSNLF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 11.16 Med: 65.33 Max: 123.81
Current: 62.17
During the past 13 years, Tristel's highest ROC (Joel Greenblatt) % was 123.81%. The lowest was 11.16%. And the median was 65.33%.
TSNLF's ROC (Joel Greenblatt) % is ranked better than 91.66% of 839
companies
in the Medical Devices & Instruments industry
Industry Median: 3.94
vs TSNLF: 62.17
Tristel's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 2.80% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
The historical data trend for Tristel's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSNLF vs ISRG, BDX, MDLN: ROC (Joel Greenblatt) % Comparison
For the Medical Instruments & Supplies subindustry, Tristel's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tristel ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tristel's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Tristel's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 62.36% mean?
Tristel (TSNLF) has a ROC (Joel Greenblatt) % of 62.36% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Tristel and its competitors. This is near median its historical median of 65.33. Over the past decade, Tristel's ROC (Joel Greenblatt) % has ranged from 11.16 to 123.81. According to the industry distribution chart, Tristel ranks #70 out of 839 companies in the Medical Devices & Instruments industry, placing it in the top 8.3%.
Is Tristel's ROC (Joel Greenblatt) % too high?
Tristel's current ROC (Joel Greenblatt) % of 62.36% is near median its 10-year median of 65.33. Over the past 10 years, this metric has ranged from a low of 11.16 to a high of 123.81. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 3.94. Tristel's value of 62.36% is 1482.7% above this industry median. Based on the distribution chart, Tristel ranks #70 out of 839 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Tristel has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tristel's ROC (Joel Greenblatt) % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Tristel ranks #70 out of 839 companies for ROC (Joel Greenblatt) %. This places Tristel in the top 8% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 3.94. Tristel's value of 62.36% is 1482.7% above this benchmark. Historically, Tristel's own ROC (Joel Greenblatt) % has ranged from 11.16 to 123.81 over the past decade. While the company's 10-year median is 65.33 vs. the industry median of 3.94, Tristel has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 3.94, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tristel's current ROC (Joel Greenblatt) % of 62.36% is 1482.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Tristel and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 3.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tristel's current ROC (Joel Greenblatt) % is 62.36%, which is near median its own 10-year median of 65.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tristel stock overvalued right now?
Based on GuruFocus' analysis, Tristel (TSNLF) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.80, compared to a current price of $5.28 — trading 22.4% below its estimated fair value. The current ROC (Joel Greenblatt) % is 62.36%, which is near median its 10-year median of 65.33 and 1482.7% above the Medical Devices & Instruments industry median of 3.94. Tristel's overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Tristel (TSNLF), the current ROC (Joel Greenblatt) % is 62.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tristel (TSNLF) Overvalued in 2026?
Based on GuruFocus' analysis, Tristel stock appears to be undervalued.
The current stock price of $5.28 is trading 22.4% below its estimated GF Value™ of $6.80.
GuruFocus considers Tristel to be Modestly Undervalued.
Key valuation signals for TSNLF:
ROC (Joel Greenblatt) %: 62.36% (near median its 10-year median of 65.33)
GF Value™: $6.80 vs. price of $5.28 (22.4% below fair value)
Industry Position: 1482.7% above the Medical Devices & Instruments median (#70 of 839)
No single metric tells the full story. See the TSNLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tristel PLC's business is the sale to hospitals of its proprietary chlorine dioxide chemistry used for the decontamination of medical devices under the Tristel brand and for the sporicidal disinfection of environmental surfaces under the Cache brand. Its operating segments include hospital medical device decontamination products used predominantly for infection control in hospitals; the manufacture and sale of hospital environmental surface disinfection products; and pharmaceutical and personal care product manufacturing industries, veterinary and animal welfare. The company generates the majority of its revenue from hospital medical device decontamination and operates geographically in the UK and overseas markets.
97GF Score
Get the complete analysis for TSNLF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSNLF has been successfully added to your 
